Fig. 1: High blood sGPNMB levels correlate significantly with tumor progression at 12 weeks post-ICI treatment. | Communications Medicine

Fig. 1: High blood sGPNMB levels correlate significantly with tumor progression at 12 weeks post-ICI treatment.

From: Acquired resistance to immune checkpoint therapy is caused by glycoprotein non-metastatic melanoma protein B signal cascade

Fig. 1

RCC patients (n = 42) were evaluated for tumor response at 12 weeks post-therapy and determined for sGPNMB levels and myeloid-derived suppressor cells (MDSC) frequencies in blood samples drawn at the same time point. Patients were sorted into responders (stable disease (SD)/partial response (PR)) and non-responders (progressive disease (PD)). % total population or GPNMB+ subpopulation of monocytic (M)-MDSC (a) or granular (G)-MDSC (b) in responders vs. non-responders. Blood levels of sGPNMB (c), sPDL1 (d), and sVEGF (e) between responders vs. non-responders. f Correlation between tumor size and blood sGPNMB levels at 12 weeks. p values are shown, and analyzed by Pearson Correlation Coefficient or Mann–Whitney U test.

Back to article page